Biomedical Research Funding


The growth and sustainability of the entire continuum of research and development is needed to ensure that life-saving gene and cell therapies are available to the patients who need them. The field of regenerative medicine is a powerful example of the benefits investing in basic and translational research can have in the development of therapeutics.

Currently, there is significant gap in the financial security for those carrying out research to demonstrate safety and efficacy in hopes of launching a product to market. This stems from a lack of funding for early phases of clinical testing, low venture capital investments in new and emerging companies, and unique clinical trial requirements such as long term follow up. The result is that many viable gene and cell therapies are abandoned early in the development process or are unable to be sustained over time.

In addition, ASGCT recognizes that clinical research should continue to inspire new research that advances therapeutic options for patients. This cycle of research improves patient care and encourages aspiring scientists and physicians to develop future regenerative medicines. In order to ensure that the field continues to grow for years to come, ASGCT should partner with coalitions and further develop their relationships with HHS and NIH officials to advocate for robust funding for basic, translational, and clinical research and focus on policy that will facilitate the success of young investigators.

Pillar 1: Education and Awareness

Significant advancements have been made over many years by ASGCT members, and several therapeutic approaches that have the potential to dramatically improve the lives of patients are expected to be available in the clinic the next few years.

Pillar 3: Value of Gene and Cell Therapy

Conversations about value will shape how gene and cell therapies will be viewed by the market. Additionally, those views will impact clinical adoption and reimbursement. There are now clear examples of product unsustainability when high treatment costs and lack of insurance coverage create barriers to access.

2019
22nd Annual Meeting
April 29 – May 2 | Washington D.C.
Close